Brought to you by 
Five Prime and bluebird bio team up to develop new CART therapies
01 Feb 2023
Executive Summary
Five Prime Therapeutics Inc. granted bluebird bio Inc. exclusive rights to antibodies against an undisclosed target, which bluebird will develop into chimeric antigen receptor T-cell (CART) therapies for solid and blood cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Five Prime and bluebird bio team up to develop new CART therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice